Tacrolimus: all 601 studies that test it

Page 2 of 7. Open to participants first (54), then studies with results posted, then the rest; newest registration first within each.

• A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell TransplantCompletedNCT02206035Phase 2Results posted
• Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative RegimenTerminatedNCT02199041Phase 2Results posted
• Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal DiseaseCompletedNCT02158052Not applicableResults posted
• Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a TransplantCompletedNCT02118896Phase 3Results posted
• REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategyCompletedNCT02115113Phase 3Results posted
• Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)TerminatedNCT02080195Phase 1/2Results posted
• Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or TacrolimusCompletedNCT02016625Phase 1Results posted
• Conversion From Brand to Generic Tacrolimus in High Risk Transplant RecipientsCompletedNCT02014103Phase 4Results posted
• Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host DiseaseCompletedNCT01977781Phase 1Results posted
• Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.CompletedNCT01962922Phase 3Results posted
• In Vivo Treg Expansion and Graft-Versus-Host Disease ProphylaxisCompletedNCT01927120Phase 2Results posted
• Role of Everolimus in Highly Sensitized PatientsCompletedNCT01911546Phase 2Results posted
• Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaCompletedNCT01904136Phase 1/2Results posted
• Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With TacrolimusCompletedNCT01887171Not applicableResults posted
• Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)CompletedNCT01884571Phase 2Results posted
• Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01871441Phase 2Results posted
• Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in ChildrenCompletedNCT01858740Phase 2Results posted
• Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive RegimenTerminatedNCT01856257Phase 2Results posted
• 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant PatientsCompletedNCT01843348Phase 3Results posted
• Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord TransplantationCompletedNCT01810588Phase 2Results posted
• Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell TransplantCompletedNCT01790568Phase 2Results posted
• Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01789255Phase 2Results posted
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic MalignanciesCompletedNCT01760655Phase 2Results posted
• Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney TransplantCompletedNCT01666951Phase 2Results posted
• Pharmacogenetic Trial of Tacrolimus After Pediatric TransplantationCompletedNCT01655563Phase 2Results posted
• Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive RegimensCompletedNCT01653847Not applicableResults posted
• Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant RecipientsCompletedNCT01649427Phase 4Results posted
• T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic TransplantTerminatedNCT01621477Phase 2Results posted
• Crohn's Allogeneic Transplant StudyTerminatedNCT01570348Phase 2Results posted
• Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)CompletedNCT01438710Phase 3Results posted
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological MalignanciesCompletedNCT01384513Phase 2Results posted
• Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative DonorCompletedNCT01350245Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic MalignanciesCompletedNCT01341301Phase 2Results posted
• Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow TransplantationCompletedNCT01338987Phase 2Results posted
• Research Study of ATG and Rituximab in Renal TransplantationTerminatedNCT01318915Early Phase 1Results posted
• A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell DiseaseTerminatedNCT01279616Phase 2Results posted
• A Pilot Study Comparing the Use of Low-target Versus Conventional Target AdvagrafCompletedNCT01265537Not applicableResults posted
• Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant PatientsCompletedNCT01256294Phase 4Results posted
• Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCTCompletedNCT01246206Phase 2Results posted
• Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic MalignanciesCompletedNCT01203722Phase 1/2Results posted
• Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney TxCompletedNCT01187953Phase 3Results posted
• Tandem Auto-Allo Transplant for LymphomaCompletedNCT01181271Phase 2Results posted
• Renal Allograft Function and Histology Following Switching From A Tacrolimus to Sirolimus (SRL)-Based Immunosuppression-TerminatedNCT01166724Phase 3Results posted
• Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in ChildrenCompletedNCT01162005Phase 4Results posted
• Campath, Calcineurin Inhibitor Reduction and Chronic Allograft NephropathyCompletedNCT01120028Phase 2/3Results posted
• Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell TransplantTerminatedNCT01118013Phase 2Results posted
• Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell TransplantationTerminatedNCT01116232Phase 2Results posted
• Calcineurin Inhibitor Sparing After Kidney TransplantationCompletedNCT01062555Phase 1/2Results posted
• Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01028716Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01027000Phase 2Results posted
• Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant RecipientsCompletedNCT01025817Phase 3Results posted
• Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaCompletedNCT01008462Phase 2Results posted
• Sirolimus Conversions in African-American Renal Transplant RecipientsCompletedNCT01005706Not applicableResults posted
• A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic EthnicityTerminatedNCT00983645Phase 4Results posted
• Tacrolimus Versus Prednisolone for the Treatment of Minimal Change DiseaseCompletedNCT00982072Phase 4Results posted
• Low Dose Thymoglobulin to Protect Kidney Function After Liver TransplantCompletedNCT00970073Not applicableResults posted
• Tacrolimus to Sirolimus Conversion for Delayed Graft FunctionTerminatedNCT00931255Phase 4Results posted
• Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHDTerminatedNCT00914940Phase 2Results posted
• Optima: Optimizing Prograf Therapy in Maintenance Allografts IICompletedNCT00905515Phase 4Results posted
• Kidney Biopsy Controlled Trial of Calcineurin Inhibitor WithdrawalCompletedNCT00896012Phase 4Results posted
• Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous GlomerulonephritisCompletedNCT00843856Phase 4Results posted
• Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver TransplantationCompletedNCT00821587Phase 4Results posted
• Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic CancerTerminatedNCT00818961Phase 2Results posted
• Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice DailyCompletedNCT00817206Phase 3Results posted
• Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell TransplantCompletedNCT00810602Phase 1/2Results posted
• Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney TransplantationCompletedNCT00807144Phase 4Results posted
• Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic CancerCompletedNCT00789776Phase 1/2Results posted
• Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic CancerCompletedNCT00782379Phase 2Results posted
• Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant PatientsCompletedNCT00772148Phase 2Results posted
• Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant PatientsCompletedNCT00765661Phase 2Results posted
• Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft StatusTerminatedNCT00731874Phase 4Results posted
• Steroid Withdrawal in Pediatric Renal Transplant: Impact on Growth, Bone Metabolism and Acute RejectionCompletedNCT00707759Phase 3Results posted
• Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host DiseaseCompletedNCT00686855Phase 2Results posted
• Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return VisitCompletedNCT00654355Phase 4Results posted
• Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell TransplantCompletedNCT00639717Phase 2Results posted
• Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney TransplantationCompletedNCT00629122Phase 4Results posted
• Allogeneic Hematopoietic Cell Transplantation for Severe Systemic SclerosisCompletedNCT00622895Phase 1/2Results posted
• Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant RecipientsCompletedNCT00622869Phase 3Results posted
• LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune HepatitisTerminatedNCT00608894Phase 2Results posted
• Pharmacokinetics of LCP-Tacro in Stable Liver Transplant PatientsCompletedNCT00608244Phase 2Results posted
• Allogeneic Stem Cell Transplant for Patients With Severe Aplastic AnemiaTerminatedNCT00578903Phase 2Results posted
• Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous LeukemiaCompletedNCT00553202Phase 2Results posted
• Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune SystemCompletedNCT00520130Phase 1/2Results posted
• Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMTCompletedNCT00506922Phase 1/2Results posted
• Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant TacrolimusCompletedNCT00504348Phase 2/3Results posted
• Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant PatientsCompletedNCT00496483Phase 2Results posted
• Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based RegimenCompletedNCT00448357Phase 1/2Results posted
• Islet Allotransplantation With Steroid Free ImmunosuppressionCompletedNCT00446264Phase 2Results posted
• Immunotherapy of the Paraneoplastic SyndromesCompletedNCT00378326Not applicableResults posted
• Single Center Pilot Study of Corticosteroid Discontinuation in Liver Transplant RecipientsCompletedNCT00374231Phase 4Results posted
• Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell TransplantationCompletedNCT00369226Phase 1/2Results posted
• A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant RecipientsCompletedNCT00369161Phase 4Results posted
• Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited DisordersTerminatedNCT00358657Phase 2Results posted
• Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous LeukemiaCompletedNCT00322101Phase 3Results posted
• Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)CompletedNCT00296296Phase 4Results posted
• Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant RecipientsCompletedNCT00284934Phase 3Results posted
• A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant PatientsCompletedNCT00282568Phase 2Results posted
• Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell TransplantationCompletedNCT00282282Phase 2Results posted
• A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant PatientsCompletedNCT00282256Phase 2Results posted
• A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant PatientsCompletedNCT00282243Phase 2Results posted

← Tacrolimus overview